* patients who have required hospitalization. * patients who have required intensive care. * patients who do not sign the informed consent. * any condition that in the investigator's judgement might interfere with study procedures or the ability of the patient to adhere to and complete the study. * patients who have been participating in any other clinical trial. * severe liver failure (child pugh score ≥ c, transaminase\>5 times the upper limit of normal (uln). * severe renal failure (gfr ≤30 ml/min/1.73 m2) or continuous dialysis (hemodialysis, peritoneal dialysis) or continuous renal replacement therapy. * severe cardiac disease. * history of hypersensitivity to either ribavirin/favipiravir. * pregnant or breast-feeding. * patients who cannot use appropriate contraceptive method during and after the study. * patients who are treated with any other treatment agent for covid-19 in the last 90 days. * patients who had covid-19 vaccination. * patients who had ribavirin/favipiravir for any reason in the past 72 hours.

* patients who have required hospitalization. * patients who have required intensive care. * patients who do not sign the informed consent. * any condition that in the investigator's judgement might interfere with study procedures or the ability of the patient to adhere to and complete the study. * patients who have been participating in any other clinical trial. * severe liver failure (child pugh score ≥ c, transaminase\>5 times the upper limit of normal (uln). * severe renal failure (gfr ≤30 ml/min/1.73 m2) or continuous dialysis (hemodialysis, peritoneal dialysis) or continuous renal replacement therapy. * severe cardiac disease. * history of hypersensitivity to either ribavirin/favipiravir. * pregnant or breast-feeding. * patients who cannot use appropriate contraceptive method during and after the study. * patients who are treated with any other treatment agent for covid-19 in the last 90 days. * patients who had covid-19 vaccination. * patients who had ribavirin/favipiravir for any reason in the past 72 hours.

- patients who have required hospitalization. - patients who have required intensive care. - patients who do not sign the informed consent. - any condition that in the investigator's judgement might interfere with study procedures or the ability of the patient to adhere to and complete the study. - patients who have been participating in any other clinical trial. - severe liver failure (child pugh score ≥ c, transaminase>5 times the upper limit of normal (uln). - severe renal failure (gfr ≤30 ml/min/1.73 m2) or continuous dialysis (hemodialysis, peritoneal dialysis) or continuous renal replacement therapy. - severe cardiac disease. - history of hypersensitivity to either ribavirin/favipiravir. - pregnant or breast-feeding. - patients who cannot use appropriate contraceptive method during and after the study. - patients who are treated with any other treatment agent for covid-19 in the last 90 days. - patients who had covid-19 vaccination. - patients who had ribavirin/favipiravir for any reason in the past 72 hours.

- patients who have required hospitalization. - patients who have required intensive care. - patients who do not sign the informed consent. - any condition that in the investigator's judgement might interfere with study procedures or the ability of the patient to adhere to and complete the study. - patients who have been participating in any other clinical trial. - severe liver failure (child pugh score ≥ c, transaminase>5 times the upper limit of normal (uln). - severe renal failure (gfr ≤30 ml/min/1.73 m2) or continuous dialysis (hemodialysis, peritoneal dialysis) or continuous renal replacement therapy. - severe cardiac disease. - history of hypersensitivity to either ribavirin/favipiravir. - pregnant or breast-feeding. - patients who cannot use appropriate contraceptive method during and after the study. - patients who are treated with any other treatment agent for covid-19 in the last 90 days. - patients who had covid-19 vaccination. - patients who had ribavirin/favipiravir for any reason in the past 72 hours.